10,070 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by Jump Financial LLC

Jump Financial LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 10,070 shares of the company's stock, valued at approximately $3,087,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Medpace by 2.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company's stock worth $2,114,000 after buying an additional 148 shares during the period. Portside Wealth Group LLC lifted its holdings in Medpace by 14.8% during the fourth quarter. Portside Wealth Group LLC now owns 1,419 shares of the company's stock valued at $435,000 after purchasing an additional 183 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Medpace by 355.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company's stock worth $1,090,000 after purchasing an additional 2,774 shares during the period. Norden Group LLC increased its stake in shares of Medpace by 207.8% in the fourth quarter. Norden Group LLC now owns 5,014 shares of the company's stock worth $1,537,000 after purchasing an additional 3,385 shares in the last quarter. Finally, Retirement Systems of Alabama raised its position in shares of Medpace by 0.3% during the 4th quarter. Retirement Systems of Alabama now owns 62,106 shares of the company's stock valued at $19,037,000 after purchasing an additional 204 shares during the period. Institutional investors own 77.98% of the company's stock.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO August J. Troendle sold 100,000 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the sale, the chief executive officer now directly owns 4,833,019 shares of the company's stock, valued at approximately $1,995,940,186.62. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of Medpace stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the completion of the transaction, the insider now owns 5,539,947 shares of the company's stock, valued at approximately $2,170,274,237.25. The disclosure for this sale can be found here. Insiders have sold 209,224 shares of company stock worth $84,618,441 over the last 90 days. 20.30% of the stock is currently owned by company insiders.

Medpace Stock Performance

Medpace stock traded down $9.01 during mid-day trading on Friday, reaching $390.19. 251,470 shares of the company were exchanged, compared to its average volume of 269,637. Medpace Holdings, Inc. has a 12-month low of $197.39 and a 12-month high of $421.00. The business has a fifty day moving average of $397.45 and a 200 day moving average of $337.15. The firm has a market cap of $12.09 billion, a P/E ratio of 39.77, a PEG ratio of 1.94 and a beta of 1.40.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating the consensus estimate of $2.45 by $0.75. The company had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. Medpace's revenue was up 17.7% compared to the same quarter last year. During the same period last year, the firm earned $2.27 earnings per share. Sell-side analysts predict that Medpace Holdings, Inc. will post 11.23 EPS for the current year.

Analyst Upgrades and Downgrades

MEDP has been the subject of a number of research analyst reports. StockNews.com upgraded Medpace from a "hold" rating to a "buy" rating in a research report on Tuesday, April 23rd. Robert W. Baird boosted their price target on shares of Medpace from $446.00 to $454.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 24th. Guggenheim increased their price objective on shares of Medpace from $453.00 to $464.00 and gave the company a "buy" rating in a research report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a report on Monday, March 18th. They issued a "hold" rating and a $395.00 target price on the stock. Finally, Jefferies Financial Group upgraded Medpace from a "hold" rating to a "buy" rating and lifted their price target for the stock from $340.00 to $450.00 in a research report on Tuesday, April 23rd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $443.00.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.